|
|
 |
|
Viewing report
|
|
|
|
Pipeline/Commercial Insight: Supportive Care In Oncology - Significant Growth Opportunities Exist In New Supportive Care Indications
Datamonitor, June 2007, Pages: 241
Supportive care can be defined as those products used to prevent and/or treat the adverse side effects that arise as a result of the tumor itself or administration of anticancer therapies, in particular cytotoxic chemotherapy.
While the antihormonal therapies and novel molecular targeted therapies do not exist without some toxicity, these are not as severe as those associated with chemotherapy.
Scope of this title:
- Overview of the current oncology supportive care market, including profiles of key marketed products and events impacting each during 2006-16
- Examination of the oncology supportive care pipeline with in-depth clinical and commercial profiles of Phase III and some key Phase II candidates
- Seven-market sales forecasts from 2006 to 2016 for branded oncology supportive care products and key pipeline candidates
- Detailed discussion of key strategic issues in the oncology supportive care market, including one commercial impact case study
Highlights of this title:
A small growth rate of 0.6% CAGR is expected in the oncology supportive care market, with seven-market sales forecast to increase from $13,763m in 2006 to $14,679m in 2016. This low level of growth is largely due to an increasing level of patent expiry and introduction of generic competition onto the market, including the impending launch of biosimilars in the EU.
While the largest commercial opportunity is predicted to occur in those new supportive care indications such as EGFR-associated skin rash, some breakthroughs will be made via the current pipeline. Treatment of thrombocytopenia is expected to be transformed with the potential launches of GlaxoSmithKline’s Promacta (eltrombopag) and Amgen’s AMG-531, while the skeletal events market is set for a treatment revolution as Amgen’s denosumab is launched. Unfortunately, the outlook for the erythropoietins class is not bright at present, following the emergence of dubious safety data and the subsequent imposition of FDA restrictions.
Reasons to order your copy:
- Understand market specific drivers and predict the future potential of key marketed and pipeline oncology supportive care products
- Assess the impact of product launches and identify the opportunities and risks for key products within the oncology supportive care market
- Adopt knowledge to drive strategic planning for marketed products and optimize the market penetration of new entrants
Coverage: Seven major markets (the US, Japan, France, Germany, Italy, Spain, and the UK)
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Stakeholder Insight: Supportive Care in Cancer Treatment - Some First-Generation Products Proving Difficult to Dislodge
Cancer Market Top 20 Drugs - Supportive Care Grows the Cancer Market
Pipeline Insight: Breast Cancer - Recent Approvals Increase Pressure On Pipeline Candidates
Competitive Insights to Anti-Angiogenic Drug R&D in Oncology
Triple Analysis: The Drug Target Atlas of Apoptopic Drugs in Oncology and Special Focus on Lung Cancer and Melanoma
Pipeline Insight: Cancer Overview - Gastrointestinal, Skin, Sarcomas
Oncology Devices Clinical Trial Analysis
The Anti-Infectives Market Outlook to 2013: Competitive Landscape, Pipeline Analysis and Growth Opportunities
Commercial and Pipeline Insight: Opioids - Short Acting and Anti-abuse Technologies Set to Fragment and Grow the Market
Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor types
Cancer Therapeutics - Market Insight and R&D Pipeline Analysis
Antibodies in Oncology: Drug Pipeline Update 2008
|
|
|
|
